A Phase II Clinical Trial of a Timing/Schedule Optimized Combined-Modality Regimen: Cisplatin + Metronomic Low-Dose Interferon-α (IFN-α) Followed by Gemcitabine HCl (GEMZAR) in Combination With Mild, Fever-Range Whole-Body Hyperthermia (FR-WBH) in Patients With Advanced, Inoperable Pancreatic Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Gemcitabine; Interferon alpha
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2012 Biomarkers information updated
- 10 Feb 2012 Planned number of patients changed from 18 to 48 as reported by ClinicalTrials.gov.
- 10 Feb 2012 Planned end date (1 Nov 2012) added as reported by ClinicalTrials.gov.